Subthalamic nucleus deep brain stimulation (STN-DBS) provides lasting benefits for patients with moderate-to-advanced Parkinson’s disease (PD), with sustained improvements in movement and quality of life, new long-term data from the INTREPID trial showed.

“Although STN-DBS outcomes declined slightly, possibly due to the progressive nature of the disease, patients with PD sustained significant improvement in motor and activities of daily living scores, along with a stable reduction in anti-parkinsonian medication over the 5-year follow-up period,” the authors wrote.

The 5-year outcomes were published online on September 15 in JAMA Neurology.

Source: MEDspace